People · Operator
Named in public records as an officer, director or promoter · active 2009–2025 · Biotechnology, Other Technology, Investment Vehicle, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| G.I. Windows, Inc. | — | Biotechnology | Series B | $76.9M | $218.3M | 2014 |
| BIND Biosciences Inc | — | Biotechnology | Series B | $51.4M | $345.2M | 2011 |
| Valentx Inc | — | Biotechnology | Series B | $40.0M | $78.2M | 2009 |
| Circonus, Inc. | — | Other Technology | Series A | $15.8M | $161.7M | 2019 |
| Anti Singularity Spv, Llc | — | Investment Vehicle | Seed | $2.5M | $6.2M | 2025 |
| Vivtex Corp | — | Biotechnology | Seed | $1.8M | $28.8M | 2022 |
| First Launch Dallas, LLC | — | Other | Seed | $1.2M | $6.7M | 2023 |
| Park Lane Holdings, LLC | — | Other | Seed | $1.1M | $4.6M | 2024 |
| EasyRx, LLC | — | Other Technology | Seed | $1.0M | $34.1M | 2019 |
James Wright at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside James Wright on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Robert Langer | 1 | 36 |
| Peter Barton Hutt | 1 | 14 |
| Robert S Langer | 1 | 14 |
| PAUL LAVIOLETTE | 1 | 12 |
| Noubar Afeyan | 1 | 9 |
| FRED MOLL | 1 | 8 |
| Frederic H. Moll | 1 | 8 |
| Christopher Thompson | 1 | 8 |
| Brian Kim | 1 | 8 |
| Scott Minick | 1 | 7 |
| David Neustaedter | 1 | 7 |
| Daniel S. Lynch | 1 | 6 |
| David Drahms | 1 | 6 |
| V. Kadir Kadhiresan | 1 | 5 |
| Andrea Franz | 1 | 4 |
| Omid Farokhzad | 1 | 4 |
| Edward Schnipper | 1 | 4 |
| Amir H. Nashat | 1 | 3 |
| Brian Tinkham | 1 | 3 |
| Omid C. Farokhzad | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.